Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

belantamab mafodotin-blmf

belantamab mafodotin-blmf
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Blenrep POWDER FOR INJECTION, INTRAVENOUS 100 mg      
Comments:

Rare need expected. Extensive REMS requirements hinder ability to utilize this agent currently.

 

Withdrawn from the US market prior to January 2025.

 

Reviewed: Sept. 2021

Last updated: Feb. 3, 2025






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2025 Rpharmy, LLC ­ All Rights Reserved